Coldstream Capital Management Inc. Boosts Position in ResMed Inc. (NYSE:RMD)

Coldstream Capital Management Inc. increased its holdings in ResMed Inc. (NYSE:RMD) by 28.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,677 shares of the medical equipment provider’s stock after acquiring an additional 595 shares during the period. Coldstream Capital Management Inc.’s holdings in ResMed were worth $460,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Handelsbanken Fonder AB lifted its position in shares of ResMed by 22.5% in the 4th quarter. Handelsbanken Fonder AB now owns 70,272 shares of the medical equipment provider’s stock worth $12,088,000 after purchasing an additional 12,899 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ResMed by 13.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,231 shares of the medical equipment provider’s stock worth $7,781,000 after buying an additional 5,517 shares during the period. Vaughan David Investments LLC IL purchased a new position in shares of ResMed during the 4th quarter worth approximately $29,322,000. Los Angeles Capital Management LLC raised its position in shares of ResMed by 647.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 13,491 shares of the medical equipment provider’s stock worth $2,321,000 after acquiring an additional 11,685 shares in the last quarter. Finally, ICW Investment Advisors LLC lifted its stake in shares of ResMed by 2.3% in the 4th quarter. ICW Investment Advisors LLC now owns 11,303 shares of the medical equipment provider’s stock valued at $1,944,000 after purchasing an additional 249 shares during the period. Institutional investors own 54.98% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on RMD. UBS Group increased their price objective on ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Oppenheimer lowered their price target on shares of ResMed from $205.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Royal Bank of Canada boosted their price objective on shares of ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a research note on Friday, April 26th. KeyCorp raised their target price on shares of ResMed from $227.00 to $238.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Finally, Mizuho reissued a “buy” rating and issued a $215.00 price target on shares of ResMed in a research report on Wednesday, March 27th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $202.80.

ResMed Price Performance

Shares of NYSE RMD opened at $211.58 on Friday. The firm has a market cap of $31.08 billion, a P/E ratio of 32.50, a PEG ratio of 2.16 and a beta of 0.64. ResMed Inc. has a twelve month low of $132.24 and a twelve month high of $229.97. The company has a quick ratio of 1.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average of $199.70 and a 200 day moving average of $181.71.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.22. ResMed had a return on equity of 24.43% and a net margin of 20.91%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business earned $1.68 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. As a group, research analysts expect that ResMed Inc. will post 7.64 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Thursday, May 9th will be issued a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Wednesday, May 8th. ResMed’s payout ratio is presently 29.49%.

Insider Transactions at ResMed

In related news, Director Karen Drexler sold 425 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $214.92, for a total transaction of $91,341.00. Following the transaction, the director now owns 8,446 shares in the company, valued at $1,815,214.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Witte Jan De sold 360 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $218.29, for a total value of $78,584.40. Following the transaction, the director now owns 7,519 shares of the company’s stock, valued at $1,641,322.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen Drexler sold 425 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $214.92, for a total transaction of $91,341.00. Following the sale, the director now directly owns 8,446 shares of the company’s stock, valued at $1,815,214.32. The disclosure for this sale can be found here. Insiders sold 15,749 shares of company stock worth $3,398,025 over the last three months. 1.21% of the stock is currently owned by company insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.